Who owns AN2 THERAPEUTICS INC?
- Ticker: ANTX
- CUSIP Number: 037326105
Tip: Access positions for across all investors
Analyze quarterly positions in An2 Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of An2 Therapeutics stock
Who bought or sold AN2 THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Vivo Capital | 3.2M | $11M | 100% | Mar 2026 |
|
| Commodore Capital | 2.3M | $8.0M | 100% | Mar 2026 |
|
| Millennium Management | 2.2M | $7.6M | 2223% | Mar 2026 |
|
| Almitas Capital | 1.5M | $5.1M | 0% | Mar 2026 |
|
| Vanguard Group | 1.1M | $1.2M | 0% | Dec 2025 |
|
| Vanguard Capital Management | 1.0M | $3.5M | 100% | Mar 2026 |
|
| Woodline Partners | 994k | $3.4M | 581% | Mar 2026 |
|
| Ameriprise Financial | 696k | $2.4M | 100% | Mar 2026 |
|
| Stonepine Capital Management | 628k | $716k | 11% | Dec 2025 |
|
| Ally Bridge Group | 526k | $1.8M | 100% | Mar 2026 |
|
| Bank of Nova Scotia | 459k | $1.6M | 0% | Mar 2026 |
|
| Bank of America Corporation | 394k | $1.3M | 100% | Mar 2026 |
|
| Renaissance Technologies | 339k | $386k | -12% | Dec 2025 |
|
| BlackRock | 319k | $1.1M | -1% | Mar 2026 |
|
| Jane Street | 304k | $1.0M | 1593% | Mar 2026 |
|
| Landscape Capital Management | 298k | $1.0M | -31% | Mar 2026 |
|
| Geode Capital Management | 287k | $981k | 14% | Mar 2026 |
|
| Bank Of Montreal | 260k | $890k | 100% | Mar 2026 |
|
| Morgan Stanley | 234k | $801k | 2% | Mar 2026 |
|
| Cantor Fitzgerald, L. P. | 200k | $684k | 100% | Mar 2026 |
|
| Seven Fleet Capital Management | 200k | $683k | 100% | Mar 2026 |
|
| Citadel Advisors | 155k | $531k | 34% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 138k | $471k | 100% | Mar 2026 |
|
| State Street Corporation | 87k | $99k | 0% | Dec 2025 |
|
| Centiva Capital | 75k | $257k | 100% | Mar 2026 |
|
| UBS Group | 61k | $210k | 8% | Mar 2026 |
|
| Bridgeway Capital Management | 60k | $68k | 0% | Dec 2025 |
|
| Peapod Lane Capital | 60k | $207k | -90% | Mar 2026 |
|
| Northern Trust | 43k | $49k | 0% | Dec 2025 |
|
| Captrust Financial Advisors | 40k | $46k | 0% | Dec 2025 |
|
| Persistent Asset Partners | 38k | $131k | 100% | Mar 2026 |
|
| Hudson Bay Capital Management | 35k | $118k | 100% | Mar 2026 |
|
| Hrt Financial | 33k | $112k | 100% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 30k | $103k | 9827% | Mar 2026 |
|
| Susquehanna International | 22k | $25k | 100% | Dec 2025 |
|
| Citigroup | 19k | $65k | 100% | Mar 2026 |
|
| OMERS Administration Corporation | 16k | $54k | 100% | Mar 2026 |
|
| ADAR1 Capital Management | 14k | $47k | 100% | Mar 2026 |
|
| Private Advisor | 13k | $43k | -44% | Mar 2026 |
|
| Qube Research & Technologies | 10k | $12k | 0% | Dec 2025 |
|
| Federated Investors | 8.3k | $29k | -28% | Mar 2026 |
|
| Vanguard Global Advisers | 7.3k | $25k | 100% | Mar 2026 |
|
| Caitong International Asset Management | 2.6k | $8.9k | 100% | Mar 2026 |
|
| Tower Research Capital | 2.0k | $2.3k | -4% | Dec 2025 |
|
| FMR | 1.2k | $1.4k | 20% | Dec 2025 |
|
| Advisor Group Holdings | 300.00 | $342.000000 | 0% | Dec 2025 |
|
| SBI Securities | 201.00 | $686.997900 | 0% | Mar 2026 |
|
Who sold out of An2 Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Pfizer | Dec 2025 | 715k | $815k |
| Two Sigma Advisers | Dec 2025 | 265k | $302k |
| Two Sigma Investments | Dec 2025 | 179k | $204k |
| Rangeley Capital | Dec 2025 | 65k | $74k |
| Squarepoint Ops | Dec 2025 | 62k | $70k |
| XTX Topco | Sep 2025 | 19k | $24k |
| Schonfeld Strategic Advisors | Dec 2025 | 14k | $16k |
| Valeo Financial Advisors | Dec 2025 | 10k | $12k |